Search Results

Bayer AG and Asklepios BioPharmaceutical, Inc. announced that the first patient has been randomized in GenePHIT, a Phase II trial of AB-1002 for the treatment of congestive heart failure.

Asklepios BioPharmaceutical, Inc. (AskBio) today announced that the first patient has been randomized at the Ohio State University Wexner Medical Center in the Phase 1 REGENERATE MSA-101 clinical trial of AB-1005, a gene therapy being developed as a treatment for multiple system atrophy-parkinsonian type (MSA-P).

Asklepios BioPharmaceutical, Inc. today announced that 20 company abstracts will be presented at the European Society for Gene and Cell Therapy (ESGCT) 30th Congress, which is being held in Brussels, Belgium, from October 24 to 27, 2023.

ReCode Therapeutics announced today it has signed a multi-year research collaboration and option agreement with Asklepios BioPharmaceutical, Inc. (AskBio).

Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first patient has been dosed in Phase 1 / Phase 2 LION-CS101 clinical trial of patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, presented first-in-human data from a Phase 1 trial investigating AB-1002 for the treatment of patients with congestive heart failure at this year’s American Heart Association Scientific Sessions, which are being held in Philadelphia, U.S., from November 11 to 13, 2023.3,4

Asklepios BioPharmaceutical, Inc., a wholly owned and independently operated subsidiary of Bayer AG, announced that Gustavo Pesquin will become the company’s next Chief Executive Officer as of March 11, 2023.

Asklepios BioPharmaceutical, Inc. (AskBio) today announced that the FDA’s approval of a new adeno-associated virus (AAV) gene therapy to treat adults with hemophilia B marks another milestone for the advancement of AAV therapeutics and highlights the important research contributions made by AskBio Co-Founder, President and Chief Scientific Officer, R. Jude Samulski, PhD.